Taken together, our data demonstrate that the small molecule AurA inhibitor AKI603 may be used to overcome drug resistance induced by BCR-ABL-T315I mutation in CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.